TN2009000190A1 - Lingo binding molecules and pharmaceutical use thereof - Google Patents

Lingo binding molecules and pharmaceutical use thereof

Info

Publication number: TN2009000190A1
Authority: TN; Tunisia
Prior art keywords: binding molecule; binding molecules; pharmaceutical use; polynucleotide; treatment
Prior art date: 2006-11-17

Application number

TNP2009000190A

Other languages

English (en)

Inventor

Adrien Walmsley

William Leonard Wishart

Marta Cortes-Cros

Josef Prassler

Ingo Klagge

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-17

Filing date

2009-05-15

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38325542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-15 Application filed by Novartis Ag filed Critical Novartis Ag

2010-10-18 Publication of TN2009000190A1 publication Critical patent/TN2009000190A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

TNP2009000190A 2006-11-17 2009-05-15 Lingo binding molecules and pharmaceutical use thereof TN2009000190A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06124350		2006-11-17
PCT/EP2007/009880 WO2008058736A1 (fr)	2006-11-17	2007-11-15	Molécules de liaison à lingo et utilisation pharmaceutique de celles-ci

Publications (1)

Publication Number	Publication Date
TN2009000190A1 true TN2009000190A1 (en)	2010-10-18

Family

ID=38325542

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000190A TN2009000190A1 (en)	2006-11-17	2009-05-15	Lingo binding molecules and pharmaceutical use thereof

Country Status (27)

Country	Link
US (4)	US8299221B2 (fr)
EP (2)	EP2395022A1 (fr)
JP (2)	JP5647414B2 (fr)
KR (1)	KR20090078353A (fr)
CN (2)	CN101553506B (fr)
AR (1)	AR063829A1 (fr)
AT (1)	ATE502960T1 (fr)
AU (1)	AU2007321817A1 (fr)
BR (1)	BRPI0718406A2 (fr)
CA (1)	CA2669181A1 (fr)
CL (1)	CL2007003303A1 (fr)
CO (1)	CO6180433A2 (fr)
CR (1)	CR10756A (fr)
DE (1)	DE602007013445D1 (fr)
EC (1)	ECSP099332A (fr)
ES (1)	ES2363622T3 (fr)
GT (1)	GT200900121A (fr)
IL (1)	IL198313A0 (fr)
MA (1)	MA30965B1 (fr)
MX (1)	MX2009005175A (fr)
NO (1)	NO20092331L (fr)
PE (1)	PE20081392A1 (fr)
RU (1)	RU2009122514A (fr)
TN (1)	TN2009000190A1 (fr)
TW (1)	TW200831534A (fr)
WO (1)	WO2008058736A1 (fr)
ZA (1)	ZA200902409B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA05009913A (es)	2003-03-19	2005-11-04	Biogen Idec Inc	Proteina enlazadora del receptor nogo.
PT1776136E (pt)	2004-06-24	2012-12-05	Biogen Idec Inc	Tratamento de estados que envolvem desmielinização
ES2434470T3 (es)	2005-07-08	2013-12-16	Biogen Idec Ma Inc.	Anticuerpos SP35 y usos de éstos
JP5312039B2 (ja) *	2005-12-02	2013-10-09	バイオジェン・アイデック・エムエイ・インコーポレイテッド	脱髄の関与する状態の処置
JP2009544703A (ja)	2006-07-24	2009-12-17	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
WO2009048605A1 (fr) *	2007-10-11	2009-04-16	Biogen Idec Ma Inc.	Procédés destinés à traiter la neuropathie optique induite par la pression, à prévenir la dégénérescence neurale et à promouvoir la survie des cellules neuronales par le biais de l'administration d'antagonistes lingo-1 et d'agonistes trkb
EP2217697B1 (fr) *	2007-11-08	2015-06-10	Biogen MA Inc.	Utilisation des antagonistes de lingo-4 dans le traitement d'états mettant en jeu une démyélination
US8058406B2 (en)	2008-07-09	2011-11-15	Biogen Idec Ma Inc.	Composition comprising antibodies to LINGO or fragments thereof
CN103118692A (zh)	2010-04-26	2013-05-22	Atyr医药公司	与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8986681B2 (en)	2010-04-27	2015-03-24	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
AU2011248614B2 (en)	2010-04-27	2017-02-16	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8993723B2 (en)	2010-04-28	2015-03-31	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
JP5991963B2 (ja)	2010-04-29	2016-09-14	エータイアーファーマ，インコーポレイテッド	バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8986680B2 (en)	2010-04-29	2015-03-24	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
CA2797977C (fr)	2010-05-03	2019-08-20	Atyr Pharma, Inc.	Decouverte innovante de compositions therapeutiques, diagnostiques et a base d'anticorps liees a des fragments proteiques de phenylalanyl-alpha-arnt-synthetases
JP6008841B2 (ja)	2010-05-03	2016-10-19	エータイアーファーマ，インコーポレイテッド	メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8946157B2 (en)	2010-05-03	2015-02-03	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
EP2566515B1 (fr)	2010-05-03	2017-08-02	aTyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à des fragments protéiques d'arginyle-arnt synthétases
EP2566499B1 (fr)	2010-05-04	2017-01-25	aTyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
JP6008843B2 (ja)	2010-05-04	2016-10-19	エータイアーファーマ，インコーポレイテッド	グルタミル−プロリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011143482A2 (fr)	2010-05-14	2011-11-17	Atyr Pharma, Inc.	Découverte de compositions inédites de nature thérapeutique, diagnostique et à base d'anticorps contenant des fragments protéiques de phénylalanyl-bêta-arnt synthétases
WO2011146410A2 (fr)	2010-05-17	2011-11-24	Atyr Pharma, Inc.	Découverte innovante de compositions thérapeutiques, de diagnostic, et d'anticorps associées à des fragments protéiques de leucyl-arnt synthétases
JP6046607B2 (ja)	2010-05-27	2016-12-21	エータイアーファーマ，インコーポレイテッド	グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2800281C (fr)	2010-06-01	2021-01-12	Atyr Pharma, Inc.	Decouverte innovante de compositions therapeutiques, diagnostiques, et d'anticorps associes a des fragments de proteine de lysyl-tarn synthetases
CN103124561B (zh)	2010-07-12	2017-05-03	Atyr 医药公司	与天冬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8999321B2 (en)	2010-07-12	2015-04-07	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
AU2011289833C1 (en)	2010-07-12	2017-06-15	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases
WO2012021247A2 (fr)	2010-07-12	2012-02-16	Atyr Pharma, Inc.	DÉCOUVERTE INNOVANTE DE COMPOSITIONS THÉRAPEUTIQUES, DE DIAGNOSTIC ET D'ANTICORPS SE RAPPORTANT À DES FRAGMENTS PROTÉIQUES DE GLYCYL-ARNt SYNTHÉTASES
CA2808539C (fr)	2010-08-25	2021-05-25	Atyr Pharma, Inc.	Decouverte innovante de compositions therapeutiques, diagnostiques et d'anticorps associees a des fragments proteiniques des tyrosyl-arnt synthetases
AU2011311956C1 (en)	2010-10-06	2017-06-15	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases
WO2013022982A2 (fr)	2011-08-09	2013-02-14	Atyr Pharma, Inc.	Polypeptides tyrosyl-arnt synthétase pégylés
WO2013086216A1 (fr)	2011-12-06	2013-06-13	Atyr Pharma, Inc.	Aspartyl-arnt synthétases améliorées
US9822353B2 (en)	2011-12-06	2017-11-21	Atyr Pharma, Inc.	PEGylated aspartyl-tRNA synthetase polypeptides
CN104220461A (zh)	2011-12-29	2014-12-17	Atyr医药公司	天冬氨酰-tRNA合成酶-FC缀合物
WO2013112859A1 (fr)	2012-01-27	2013-08-01	New York University	Méthode d'amélioration de la remyélinisation à l'aide d'inhibiteurs gli1
US9796780B2 (en) *	2012-05-14	2017-10-24	Biogen Ma Inc.	LINGO-2 antagonists for treatment of conditions involving motor neurons
ES2708565T3 (es)	2013-03-15	2019-04-10	Atyr Pharma Inc	Conjugados de Fc-histidil-ARNt sintetasa
US10435467B2 (en)	2015-01-08	2019-10-08	Biogen Ma Inc.	LINGO-1 antagonists and uses for treatment of demyelinating disorders
CN113079470B (zh) *	2015-01-26	2025-02-18	苹果公司	提高水平和垂直定位准确性的设备和方法
JP7149257B2 (ja) *	2016-07-13	2022-10-06	バイオジェン・エムエイ・インコーポレイテッド	Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
WO2018195338A1 (fr)	2017-04-20	2018-10-25	Atyr Pharma, Inc.	Compositions et procédés pour le traitement d'inflammation pulmonaire
KR102414826B1 (ko)	2020-06-18	2022-06-30	삼성전기주식회사	코일 부품

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308573D0 (en)	1983-03-29	1983-05-05	British Nuclear Fuels Ltd	Filament impregnating/coating
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
EP0281604B1 (fr)	1986-09-02	1993-03-31	Enzon Labs Inc.	Molecules de liaison de chaines de polypeptide simples
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69024382T2 (de)	1989-02-13	1996-08-14	Schering Ag, 13353 Berlin	Fledermausspeichel-Plasminogenaktivator vPA-alpha 1
ES2352551T3 (es) *	2003-03-19	2011-02-21	Biogen Idec Ma Inc.	Proteína de unión a receptor nogo.
MXPA05009913A (es)	2003-03-19	2005-11-04	Biogen Idec Inc	Proteina enlazadora del receptor nogo.
US20050214288A1 (en)	2004-03-26	2005-09-29	Human Genome Sciences, Inc.	Antibodies against Nogo receptor
PT1776136E (pt) *	2004-06-24	2012-12-05	Biogen Idec Inc	Tratamento de estados que envolvem desmielinização
ES2434470T3 (es)	2005-07-08	2013-12-16	Biogen Idec Ma Inc.	Anticuerpos SP35 y usos de éstos

2007
- 2007-11-15 PE PE2007001587A patent/PE20081392A1/es not_active Application Discontinuation
- 2007-11-15 AR ARP070105078A patent/AR063829A1/es not_active Application Discontinuation
- 2007-11-15 EP EP11151300A patent/EP2395022A1/fr not_active Withdrawn
- 2007-11-15 BR BRPI0718406-9A patent/BRPI0718406A2/pt not_active IP Right Cessation
- 2007-11-15 KR KR1020097009952A patent/KR20090078353A/ko not_active Ceased
- 2007-11-15 DE DE602007013445T patent/DE602007013445D1/de active Active
- 2007-11-15 CN CN2007800415830A patent/CN101553506B/zh not_active Expired - Fee Related
- 2007-11-15 CA CA002669181A patent/CA2669181A1/fr not_active Abandoned
- 2007-11-15 RU RU2009122514/10A patent/RU2009122514A/ru not_active Application Discontinuation
- 2007-11-15 EP EP07846601A patent/EP2084190B1/fr not_active Revoked
- 2007-11-15 JP JP2009536654A patent/JP5647414B2/ja not_active Expired - Fee Related
- 2007-11-15 CN CN2013102559773A patent/CN103351437A/zh active Pending
- 2007-11-15 US US12/514,542 patent/US8299221B2/en not_active Expired - Fee Related
- 2007-11-15 AT AT07846601T patent/ATE502960T1/de not_active IP Right Cessation
- 2007-11-15 WO PCT/EP2007/009880 patent/WO2008058736A1/fr not_active Ceased
- 2007-11-15 MX MX2009005175A patent/MX2009005175A/es not_active Application Discontinuation
- 2007-11-15 ES ES07846601T patent/ES2363622T3/es active Active
- 2007-11-15 AU AU2007321817A patent/AU2007321817A1/en not_active Abandoned
- 2007-11-16 CL CL200703303A patent/CL2007003303A1/es unknown
- 2007-11-16 TW TW096143597A patent/TW200831534A/zh unknown
2009
- 2009-04-07 ZA ZA200902409A patent/ZA200902409B/xx unknown
- 2009-04-23 IL IL198313A patent/IL198313A0/en unknown
- 2009-04-29 CR CR10756A patent/CR10756A/es not_active Application Discontinuation
- 2009-05-12 CO CO09048055A patent/CO6180433A2/es not_active Application Discontinuation
- 2009-05-12 GT GT200900121A patent/GT200900121A/es unknown
- 2009-05-15 TN TNP2009000190A patent/TN2009000190A1/fr unknown
- 2009-05-15 EC EC2009009332A patent/ECSP099332A/es unknown
- 2009-06-03 MA MA31944A patent/MA30965B1/fr unknown
- 2009-06-17 NO NO20092331A patent/NO20092331L/no not_active Application Discontinuation
2012
- 2012-09-14 US US13/616,226 patent/US20130071400A1/en not_active Abandoned
- 2012-10-04 JP JP2012222370A patent/JP2013056888A/ja active Pending
2013
- 2013-09-26 US US14/037,841 patent/US20140037639A1/en not_active Abandoned
2014
- 2014-05-19 US US14/280,933 patent/US20140255415A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2008058736A1 (fr)	2008-05-22
US20140255415A1 (en)	2014-09-11
EP2395022A9 (fr)	2013-04-24
US20100143362A1 (en)	2010-06-10
JP5647414B2 (ja)	2014-12-24
GT200900121A (es)	2011-11-11
ECSP099332A (es)	2009-06-30
MA30965B1 (fr)	2009-12-01
DE602007013445D1 (de)	2011-05-05
BRPI0718406A2 (pt)	2013-12-17
US20130071400A1 (en)	2013-03-21
NO20092331L (no)	2009-06-17
CN103351437A (zh)	2013-10-16
ES2363622T3 (es)	2011-08-10
MX2009005175A (es)	2009-08-07
IL198313A0 (en)	2011-08-01
KR20090078353A (ko)	2009-07-17
RU2009122514A (ru)	2010-12-27
TW200831534A (en)	2008-08-01
JP2013056888A (ja)	2013-03-28
EP2084190A1 (fr)	2009-08-05
PE20081392A1 (es)	2008-11-12
CN101553506A (zh)	2009-10-07
EP2084190B1 (fr)	2011-03-23
CA2669181A1 (fr)	2008-05-22
US20140037639A1 (en)	2014-02-06
ATE502960T1 (de)	2011-04-15
CO6180433A2 (es)	2010-07-19
ZA200902409B (en)	2010-04-28
CL2007003303A1 (es)	2008-06-27
JP2010509906A (ja)	2010-04-02
EP2395022A1 (fr)	2011-12-14
CN101553506B (zh)	2013-08-07
AR063829A1 (es)	2009-02-18
US8299221B2 (en)	2012-10-30
CR10756A (es)	2009-06-04
AU2007321817A1 (en)	2008-05-22

Publication	Publication Date	Title
TN2009000190A1 (en)	2010-10-18	Lingo binding molecules and pharmaceutical use thereof
UA100682C2 (ru)	2013-01-25	АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
NZ603570A (en)	2014-12-24	Biological materials related to her3
IL187321A0 (en)	2008-04-13	Host cell specific binding molecules capable of neutralizing viruses and uses thereof
MY177065A (en)	2020-09-03	4-1bb binding molecules
BRPI0511479A (pt)	2007-12-26	molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
MX2011013903A (es)	2012-05-08	Polipeptidos quimericos y usos de los mismos.
WO2008065372A3 (fr)	2008-10-23	Polypeptides d'érythropoïétine modifiés et utilisation de ceux-ci dans des traitements
MX2009002816A (es)	2009-05-28	Proteinas de fusion de albumina.
BRPI0809594A2 (pt)	2019-08-27	polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
WO2009045370A3 (fr)	2010-04-22	Constructions et bioréacteurs de commutation de gène théapeutique destinés à l'expression de molécules biothérapeutiques, et utilisation de ceux-ci
WO2008028117A3 (fr)	2008-10-23	Miméticorps glp-2, polypeptides, compositions, procédés et utilisations
MX2009001203A (es)	2009-06-01	Muteinas de lipocalina lacrimosa y metodos para obtener las mismas.
WO2007093177A3 (fr)	2007-12-21	Fragments de peptides derives de la metallothioneine
WO2007054520A3 (fr)	2007-08-09	Procedes d'identification du microarn et leurs applications en termes de recherche et de sante humaine
SI2010563T1 (sl)	2011-07-29	Sintetična MeCP2 sekvenca za proteinsko nadomestno terapijo
WO2008040190A8 (fr)	2009-07-09	Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2010011994A3 (fr)	2010-04-29	Polypeptides et leurs utilisations
TN2010000199A1 (en)	2011-11-11	Improved nogo-a binding molecules and pharmaceutical use thereof
SG146660A1 (en)	2008-10-30	Nogo-a binding molecules and pharmaceutical uses thereof
WO2010036031A3 (fr)	2010-06-24	Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer
WO2010065536A3 (fr)	2010-09-16	Antigène-2 du stroma de la moelle osseuse recombinant dans le traitement de maladies auto-immunes
TW200724679A (en)	2007-07-01	Treatment of disease using an improved regulated expression system
WO2006094813A3 (fr)	2007-03-08	Microproteines dimeriques ou multimeriques
WO2005110460A3 (fr)	2006-04-13	Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1)